
Achieve Life Sciences, Inc. (NASDAQ:QUIT – Free Report) – Analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for Achieve Life Sciences in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the company will earn ($1.38) per share for the year, down from their previous estimate of ($1.02). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q4 2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.67) EPS and FY2028 earnings at $0.28 EPS.
QUIT has been the subject of a number of other reports. Zacks Research assumed coverage on shares of Achieve Life Sciences in a report on Tuesday, November 10th. They issued a “hold” rating for the company. Weiss Ratings initiated coverage on shares of Achieve Life Sciences in a research report on Wednesday. They issued a “sell (d-)” rating on the stock. Finally, Wall Street Zen upgraded shares of Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Achieve Life Sciences currently has a consensus rating of “Reduce”.
Achieve Life Sciences Stock Up 0.5%
Shares of QUIT stock opened at $6.32 on Friday. Achieve Life Sciences has a 1 year low of $2.62 and a 1 year high of $8.64. The firm has a market cap of $695.39 million, a P/E ratio of -4.08 and a beta of 2.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.95 and a current ratio of 10.49.
About Achieve Life Sciences
Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.
Read More
- Five stocks we like better than Achieve Life Sciences
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
